References
- Yamauchi P. S., Rizk D., Lowe N. J. Retinoid therapy for psoriasis. Dermatol Clin 2004; 22: 467–76
- Gupta A. K., Goldfarb M. T., Ellis C. N., Voorhees J. J. Side‐effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989; 20: 1088–93
- Larsen F. G., Jakobsen P., Knudsen J., Weismann K., Kragballe K., Nielsen‐Kudsk F. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol 1993; 100: 623–7
- Stern D. K., Tripp J. M., Ho V. C., Lebwohl M. The use of systemic immune modulators in dermatology: an update. Dermatol Clin 2005; 23: 259–300
- Efalizumab [package insert]. , et al. Genentech, Inc, South San Francisco (CA) 2003
- Lim J. L., Stern R. S. High levels of ultraviolet B exposure increase the risk of non‐melanoma skin cancer in psoralen and ultraviolet A‐treated patients. J Invest Dermatol 2005; 124: 505–13
- Gasparro F. P. The role of PUVA in the treatment of psoriasis. Photobiology issues related to skin cancer incidence. Am J Clin Dermatol 2000; 1: 337–48
- Stern R. S., Laird N., Melski J., Parrish J. A., Fitzpatrick T. B., Bleich H. L. Cutaneous squamous‐cell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310: 1156–61
- Lebwohl M., Tannis C., Carrasco D. Acitretin suppression of squamous cell carcinoma: case report and literature review. J Dermatol Treat 2003; 14((suppl 20))3–6
- Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478–86
- Etanercept [package insert]. , et al. Amgen, Thousand Oaks (CA) 2003
- Yones S. S., Palmer R. A., Kuno Y., Hawk J. L. Audit of the use of psoralen photochemotherapy (PUVA) and narrowband UVB phototherapy in the treatment of psoriasis. J Dermatol Treat 2005; 16: 108–12
- Morrison W. L. Combination of methoxsalen and ultraviolet B (UVB) versus UVB radiation alone in the treatment of psoriasis: a bilateral comparison study. Photodermatol Photoimmunol Photomed 1995; 11: 6–8
- Van Weelden H., de la Faille H. B., Young E., van der Leun J. C. Comparison of narrowband UVB phototherapy and PUVA photochemotherapy in the treatment of psoriasis. Acta Derm Venereol 1990; 70: 212–15
- Coven T. R., Burack L. H., Gilleaudeau R., Keogh M., Ozawa M., Krueger J. G. Narrowband UV‐B produces superior clinical and histopathological resolution of moderate‐to‐severe psoriasis in patients compared with broadband UV‐B. Arch Dermatol 1997; 133: 1514–22
- Yamauchi P. S., Rizk D., Kormeili T., Patnaik R., Lowe N. J. Current systemic therapies for psoriasis. Where are we now?. J Am Acad Dermatol 2003; 49: S66–77
- Stebbins W. G., Lebwohl M. G. Biologics in combination with nonbiologics: efficacy and safety. Dermatol Ther 2004; 17: 432–40
- Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993; 28: 466–9
- Hoekstra M., van Ede A. E., Haagsma C. J. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 423–6
- Whiting‐O'Keefe Q. E., Fye K. H., Sack K. D. Methotrexate and histologic hepatic abnormalities: A meta‐analysis. Am J Med 1991; 90: 711–16
- Soriatane [package insert]. , et al. Connetics, Palo Alto (CA) 2004
- Rosenbaum M. M., Roenigk H. H Jr. Treatment of generalized pustular psoriasis with etretinate (Ro 10‐9359) and methotrexate. J Am Acad Dermatol 1984; 10((2 Pt 2))357–61
- Lowe N. J., Wieder J. M., Rosenbach A., Johnson K., Kunkel R., Bainbridge C., et al. Long‐term low‐dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996; 35: 710–19
- Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Lagman M., et al. Cyclosporine induces cancer progression by a cell‐autonomous mechanism. Nature 1999; 397: 530–4
- Krueger G. G., Ellis C. N. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 2003; 148: 784–8
- Gottlieb A. B., Casale T. B., Frankel E., Goffe B., Lowe N., Ochs H. D., et al. CD4+ T‐cell‐directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 2003; 49: 816–25